Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Breast Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 36 articles:
HTML format



Single Articles


    June 2025
  1. MAMOUNAS EP, Bandos H, White JR, Julian TB, et al
    Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
    N Engl J Med. 2025;392:2113-2124.
    PubMed     Abstract available


  2. PARTRIDGE AH
    Menopausal Symptom Management in Breast Cancer Survivors - A Promising New Option.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMe2506475.
    PubMed    


  3. CARDOSO F, Parke S, Brennan DJ, Briggs P, et al
    Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2415566.
    PubMed     Abstract available


  4. BIDARD FC, Mayer EL, Park YH, Janni W, et al
    First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
    N Engl J Med. 2025 Jun 1. doi: 10.1056/NEJMoa2502929.
    PubMed     Abstract available


    May 2025
  5. CAMPONE M, De Laurentiis M, Jhaveri K, Hu X, et al
    Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
    N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2505725.
    PubMed     Abstract available


  6. JHAVERI KL, Im SA, Saura C, Loibl S, et al
    Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
    N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2501796.
    PubMed     Abstract available


    March 2025
  7. SCHMID P, Zhou X, Dent R
    Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2025;392:1142.
    PubMed    


  8. SORSCHER S
    Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2025;392:1141-1142.
    PubMed    


  9. SUN R, Seibert TM, Wei LJ
    Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2025;392:1141.
    PubMed    


  10. NEVEN P, Floris G, Desmedt C
    Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2025;392:1140-1141.
    PubMed    


    February 2025
  11. BARDIA A, Schwaederle M, Curigliano G
    Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply.
    N Engl J Med. 2025;392:830-831.
    PubMed    


  12. CONFORTI F, Oriecuia C, Pala L
    Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
    N Engl J Med. 2025;392:830.
    PubMed    


  13. HUANG R, Chen M, Shi Y
    Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
    N Engl J Med. 2025;392:829-830.
    PubMed    


  14. WOLFF AC, McShane LM, Allison KH
    Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
    N Engl J Med. 2025;392:829.
    PubMed    


    January 2025
  15. TURNER NC, Thanopoulou E, Jhaveri KL
    Inavolisib Therapy in Advanced Breast Cancer. Reply.
    N Engl J Med. 2025;392:310-311.
    PubMed    


  16. IBRAHEEM AF, Nguyen R, Gadi VK
    Inavolisib Therapy in Advanced Breast Cancer.
    N Engl J Med. 2025;392:310.
    PubMed    


  17. GEYER CE JR, Untch M, Huang CS, Mano MS, et al
    Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
    N Engl J Med. 2025;392:249-257.
    PubMed     Abstract available


    December 2024
  18. MORROW M
    Sentinel-Lymph-Node Biopsy in Early-Stage Breast Cancer - Is It Obsolete?
    N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMe2414899.
    PubMed    


  19. REIMER T, Stachs A, Veselinovic K, Kuhn T, et al
    Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.
    N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMoa2412063.
    PubMed     Abstract available


  20. JHAVERI KL, Neven P, Casalnuovo ML, Kim SB, et al
    Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
    N Engl J Med. 2024 Dec 11. doi: 10.1056/NEJMoa2410858.
    PubMed     Abstract available


    November 2024
  21. BURSTEIN HJ
    Immunotherapy for Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2024;391:2048-2049.
    PubMed    


    October 2024
  22. GRADISHAR WJ
    Improving the Outcome of Bad-Acting Hormone Receptor-Positive Breast Cancer.
    N Engl J Med. 2024;391:1644-1647.
    PubMed    


  23. TURNER NC, Im SA, Saura C, Juric D, et al
    Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
    N Engl J Med. 2024;391:1584-1596.
    PubMed     Abstract available


    September 2024
  24. RUBIN EJ, Yeku OO, Morrissey S
    NEJM at ESMO - Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411492.
    PubMed    


  25. RUBIN EJ, Yeku OO, Morrissey S
    NEJM at ESMO - Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411488.
    PubMed    


  26. SCHMID P, Cortes J, Dent R, McArthur H, et al
    Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2409932.
    PubMed     Abstract available


  27. BARDIA A, Hu X, Dent R, Yonemori K, et al
    Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407086.
    PubMed     Abstract available


    August 2024
  28. WANDER SA, Thai JN, Wirth LJ, Soto DE, et al
    Case 26-2024: A 59-Year-Old Woman with Aphasia, Anemia, and a Breast Mass.
    N Engl J Med. 2024;391:747-757.
    PubMed    


    June 2024
  29. SLAMON D, Yardley DA, Hortobagyi G
    Ribociclib plus Endocrine Therapy in Early Breast Cancer. Reply.
    N Engl J Med. 2024;390:2221-2222.
    PubMed    


  30. TANNOCK IF, Meirson T, Fojo A
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:2220-2221.
    PubMed    


  31. LI Q, Cai Y, Li J
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:2220.
    PubMed    


  32. TU H, Zhang Y, You Z
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:2219-2220.
    PubMed    


  33. VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al
    Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
    N Engl J Med. 2024;390:2011-2022.
    PubMed    


    April 2024
  34. DE BONIFACE J, Filtenborg Tvedskov T, Ryden L, Szulkin R, et al
    Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    N Engl J Med. 2024;390:1163-1175.
    PubMed     Abstract available


  35. MCGUIRE KP
    Axillary Dissection - The Bell Tolls for Thee.
    N Engl J Med. 2024;390:1231-1232.
    PubMed    


    March 2024
  36. SLAMON D, Lipatov O, Nowecki Z, McAndrew N, et al
    Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    N Engl J Med. 2024;390:1080-1091.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.